Chikungunya virus persists in macrophages, causing long-term joint inflammation and relapsing arthralgia. Researchers use advanced techniques to map gene activity and profile individual cells, finding a 'sanctuary' where the virus replicates.
The CU Anschutz School of Medicine is launching a 3-year MD program called Peak-to-Peak Pathway to reduce the cost of medical education and address physician workforce shortages. The program will matriculate its first class in summer 2027, with students pursuing specialties such as pediatrics and rural family medicine.
The CU Anschutz School of Medicine has achieved the best ranking in NIH funding in 20 years, moving to No. 21 among all medical schools. This is attributed to the growth in NIH funding from $314 million, with nine clinical departments ranked in the top 15.
A new weight management process called PATHWEIGH has been developed by CU Anschutz faculty to help patients with weight management. The program mitigates population weight gain by 0.58 kg over 18 months and increases the likelihood of a patient receiving weight-related care by 23%.
A culturally tailored intervention utilizing community health workers has been shown to improve dialysis adherence among Hispanic and Latino patients. The Navigate-Kidney program provides patient-centered education, support, and empowerment, leading to a modest reduction in interdialytic weight gain.
A study comparing GLP-1 RAs found that all three drugs are relatively safe options for patients with type 2 diabetes, with minimal differences in kidney and cardiovascular risks. Liraglutide had a lower risk of all-cause mortality compared to dulaglutide.
A new study aimed to standardize POCUS education, leading to more physician trainees learning the technique. The research found consensus on over 50 essential skills and teaching methods, promoting better patient care with faster diagnosis times.
Heiko Yang, MD, PhD, has received a grant from the National Institutes of Health (NIH) to further research on his discovery of an earthworm-derived hemoglobin-like oxygen carrier. This substance has the potential to revolutionize organ perfusion by providing a shelf-stable alternative to donor blood.
Researchers found that tolcapone increases behavioral control in individuals with AUD by activating the prefrontal cortex, which is consistent with the drug's effects on dopamine levels. The study suggests a new mechanism for treating AUD beyond current medications that target the brain's reward system.